人口药理动力学和限量采样策略的mycophenolatemofetil为印度患者与狼性炎
Kévin Koloskoff1,2, Ritika Panwar3, Manish Rathi4
1Inserm, Pharmacology & Toxicology, U 1248, Limoges, France.
这项研究开发了一种人口药理动力学模型和3样限量采样策略,以优化印度狼性炎患者的mycophenolic acid治疗药物监测.
科学领域:
- 药理动力学 药理动力学
- 制药指标 (Pharmacometrics) 是一个指标.
- 药物监测 药物监测是指对药物进行监测.
背景情况:
- 菌酸对于治疗狼性炎 (LN) 是至关重要的.
- 其复杂的药理动力学显示出显著的个体间变异性.
- 优化治疗药物监测 (TDM) 对于有效的LN治疗至关重要.
研究的目的:
- 在印度LN患者中开发菌酸的人口药理动力学 (popPK) 模型.
- 为优化TDM创建一个3样限量采样策略 (LSS).
- 为了使在常规临床实践中有效地估计曲线下面积 (AUC).
主要方法:
- 在稳定状态下 (剂前和剂后1,2,4,6小时) 每位患者收集了5个血液样本.
- 使用Monolix软件与随机近似期望-最大化算法进行popPK分析.
- 通过模拟PK配置文件和贝叶斯估计得出并验证了一个LSS.
主要成果:
- 一个带有双玛吸收的1个隔间模型最好地描述了mycophenolic acid的药理动力学.
- 在包括共变量时没有观察到显著的改善.
- 最优的3样LSS (1,2,4小时后) 在外部数据集中表现良好.
结论:
- 开发的popPK模型准确地估计了印度成年LN患者的mycophenolic acid PK.
- 拟议的LSS简化了基于临床环境中的AUC的TDM优化.
- 这种方法促进了个性化的酸剂量,以改善LN管理.
更多相关视频
09:43Analyses of Proteinuria, Renal Infiltration of Leukocytes, and Renal Deposition of Proteins in Lupus-prone MRL/lpr Mice
Published on: June 8, 2022
06:14Optimized LC-MS/MS Method for the High-throughput Analysis of Clinical Samples of Ivacaftor, Its Major Metabolites, and Lumacaftor in Biological Fluids of Cystic Fibrosis Patients
Published on: October 15, 2017
相关概念视频
Analysis of Population Pharmacokinetic Data
Renal Failure: Dose Adjustments
Reduced renal clearance and elimination rate are common outcomes of renal impairment. These alterations lead to a prolonged elimination half-life and an altered apparent volume of distribution for drugs. As a result, dosage adjustments are typically necessary to maintain optimal drug levels in the body.
However, dosage adjustments...
Nonlinear Pharmacokinetics: Overview
Nonlinearity can arise due to the saturation of plasma protein-binding or...
Model-Independent Approaches for Pharmacokinetic Data: Noncompartmental Analysis
One important characteristic of noncompartmental analyses is that drug exposure increases proportionally with increasing doses. This...
Drug Concentrations: Measurements
Plasma...
Physiological Pharmacokinetic Models: Incorporating Hepatic Transporter-Mediated Clearance
A recent model describes pravastatin's hepatobiliary excretion,...
